secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001104659-22-116468
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q3 revenue $11.2M (+46% YoY); reaffirms FY2022 guidance $42-45M
------------------------------------------------------------------------

- Q3 revenue $11.2M, up 46% YoY; gross margin 66% vs 60% a year ago.
- Net loss $10.7M vs $8.3M; operating loss $9.5M vs $7.2M in Q3 2021.
- Reaffirmed FY2022 revenue guidance $42-45M (43-53% growth over FY2021).
- OviTex revenue +29% YoY, OviTex PRS +108% YoY; BRAVO study shows 2.6% recurrence rate.
- Closed August oversubscribed public offering netting $34.4M; cash $54.2M at quarter end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465922116468/0001104659-22-116468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465922116468/tm2230071d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-116468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer